CYTLIMIC -Cytotoxic T Lymphocyte Immunotherapy in Cancer

CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC’s products aim to activate immune systems to attack cancer cells while enabling patients to maintain a high quality-of-life during treatment.

Japanese

News Release

Registration of patent on HSP70 (Heat Shock Protein 70) peptides for cancer immunotherapy in Europe

Patent on HSP70-derived peptides, and pharmaceutical compositions comprising the peptides to treat or prevent cancer was registered in Europe. A peptide in the patent is used in CYT001, the peptide vaccine under development in Cytlimic.
read more

Registration of patent on GPC3 (Glypican-3) peptides for cancer immunotherapy in Japan

Patent on GPC3-derived peptides, and pharmaceutical compositions comprising the peptides to treat or prevent cancer was registered in Japan. A peptide in the patent is used in CYT001, the peptide vaccine under development in Cytlimic.
read more

Registration of Patent on an immune-oncology medicine in Europe

Patent on an immuno-oncology medicine comprising TLR3 agonist (e.g., Poly I:C) and LAG-3 IgG fusion protein was registered in Europe. A novel combination adjuvant based on this invention is used in CYT001, a peptide vaccine under development in Cytlimic, to boost the vaccine efficacy.
read more

Company

Name
CYTLIMIC Inc.
Business
・Clinical trial of cancer peptide vaccines
・Nonclinical testing of cancer peptide vaccines
・Developing formulations for investigational use vaccines, stability testing
・Promoting application with pharmaceutical companies
Date established
December 16, 2016
Capital
100 million yen
Address
MG Meguro Ekimae Building, 15-19, Kamiosaki 2-Chome, Shinagawa-ku, Tokyo
141-0021, Japan

Board

President and CEO

Minori Saitoh, Ph.D.

Member of the Board

Hiromichi Kimura, Ph.D.

CEO and Partner
Fast Track Initiative, Inc.
Member of the Board

Kazuo Kunieda, Ph.D.

Department Manager
Venture Fund Business Department
NEC Capital Solutions Limited
Member of the Board

Akira Kitamura

GM, AI Drug Development Division
NEC Corporation
Audit & Supervisory Board Member (KANSAYAKU)

Yoshikatsu Ichinose

Global Innovation Strategy Division
NEC Corporation

Science & Technology

aaa
aaa
aaa
aaa
aaa
aaa
aaa
aaa
aaa

Partner

Oncovir, Inc.
A pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical immunotherapies for cancer and other diseases. Oncovir Hiltonol (Poly ICLC) is supplied to Cytlimic and used in Cytlimic CYT001 cancer vaccine under collaboration agreement between Oncovir and Cytlimic, to synergistically boost patient immune responses to vaccine antigens together with Immutep Efitilagimod Alpha.
Find out more
Immutep Ltd.
A globally active biotechnology company developing LAG-3 related immunotherapeutic product. Immutep Eftilagimod Alpha (LAG-3Ig, IMP321) is supplied to Cytlimic and used in Cytlimic CYT001 cancer vaccine under collaboration agreement between Immutep and Cytlimic, to synergistically boost patient immune responses to vaccine antigens together with Oncovir Hiltonol.
Find out more

Key Publications and Presentations

Poster PresentationAACR 2020, June 2020

Nakajima M. et al., Immunological and histopathological tumor responses of a novel neoadjuvant peptide vaccine (CYT001) targeting HSP70 and GPC3 antigens in patients with resectable HCC (Poster number CT251)

Clinical Trial Summary ReportJapan Registry of Clinical Trials (JRCT), April 2020

A phase I study of combination immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol for patients with advanced or metastatic solid cancer (YNP01 study)

ArticleCancer Immunology, Immunotherapy, March 2020

Nakajima M. et al., A phase I study of multi-HLA binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial, Cancer Immunology, Immunotherapy, (On-line Article)

ArticleJournal of Immunotherapy, September 2019

Matsui H. et al., Identification of a Promiscuous Epitope Peptide Derived from HSP70, J. Immunotherapy, 42 (2019) 244-250

Oral PresentationBIO ASIA-Taiwan, July 2019

Doi S., Innovative Cancer Vaccine, a Fruit of the Integration of AI and Immunology, Session 2 – AI for Biotech & Healthcare

Poster PresentationSITC 2018, November 2018

Nakajima M. et al., AI-designed dual peptide vaccine plus novel combination adjuvant showed a markedly effective induction of antigen-specific CTLs with disease stabilization in last line pts. with GI cancers

Poster PresentationASCO 2017, June 2017

Matsui H. et al., A first in human phase I study of novel multi-HLA binding peptides and new combination of immune adjutants against solid tumors

ArticleCancer Science, April 2016

Kano Y. et al., Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion, Cancer Science, 107 (2016) 398-406

ArticleJournal of Biological Physics, June 2002

Udaka K. et al., Prediction of MHC Class I Binding Peptides by a Query Learning Algorithm Based on Hidden Markov Models, J. Biological Physics, 28 (2002) 183-194

Contact

お名前
御社名
メールアドレス
お問合わせ内容

PAGETOP